213 related articles for article (PubMed ID: 32919399)
21. Revisiting the effect of GnRH analogue treatment on bone mineral density in young adolescents with gender dysphoria.
Biggs M
J Pediatr Endocrinol Metab; 2021 Jul; 34(7):937-939. PubMed ID: 33894110
[No Abstract] [Full Text] [Related]
22. Effectiveness of Puberty Suppression with Gonadotropin-Releasing Hormone Agonists in Transgender Youth.
Mejia-Otero JD; White P; Lopez X
Transgend Health; 2021; 6(1):31-35. PubMed ID: 33614957
[No Abstract] [Full Text] [Related]
23. Leuprolide Acetate for Puberty Suppression in Transgender and Gender Diverse Youth: A Comparison of Subcutaneous Eligard Versus Intramuscular Lupron.
Eitel KB; Hodax JK; DiVall S; Kidd KM; Salehi P; Sequeira GM
J Adolesc Health; 2023 Feb; 72(2):307-311. PubMed ID: 36404242
[TBL] [Abstract][Full Text] [Related]
24. Blood Pressure Dynamics After Pubertal Suppression with Gonadotropin-Releasing Hormone Analogs Followed by Testosterone Treatment in Transgender Male Adolescents: A Pilot Study.
Perl L; Segev-Becker A; Israeli G; Elkon-Tamir E; Oren A
LGBT Health; 2020; 7(6):340-344. PubMed ID: 32735503
[No Abstract] [Full Text] [Related]
25. Alterations in the inferior fronto-occipital fasciculus - a specific neural correlate of gender incongruence?
van Heesewijk J; Steenwijk MD; Kreukels BPC; Veltman DJ; Bakker J; Burke SM
Psychol Med; 2023 Jun; 53(8):3461-3470. PubMed ID: 35301969
[TBL] [Abstract][Full Text] [Related]
26. Impact of Early Medical Treatment for Transgender Youth: Protocol for the Longitudinal, Observational Trans Youth Care Study.
Olson-Kennedy J; Chan YM; Garofalo R; Spack N; Chen D; Clark L; Ehrensaft D; Hidalgo M; Tishelman A; Rosenthal S
JMIR Res Protoc; 2019 Jul; 8(7):e14434. PubMed ID: 31290407
[TBL] [Abstract][Full Text] [Related]
27. Gender affirming medical care of transgender youth.
Salas-Humara C; Sequeira GM; Rossi W; Dhar CP
Curr Probl Pediatr Adolesc Health Care; 2019 Sep; 49(9):100683. PubMed ID: 31735692
[TBL] [Abstract][Full Text] [Related]
28. Effect of pubertal suppression and cross-sex hormone therapy on bone turnover markers and bone mineral apparent density (BMAD) in transgender adolescents.
Vlot MC; Klink DT; den Heijer M; Blankenstein MA; Rotteveel J; Heijboer AC
Bone; 2017 Feb; 95():11-19. PubMed ID: 27845262
[TBL] [Abstract][Full Text] [Related]
29. Parent reports of adolescents and young adults perceived to show signs of a rapid onset of gender dysphoria.
Littman L
PLoS One; 2018; 13(8):e0202330. PubMed ID: 30114286
[TBL] [Abstract][Full Text] [Related]
30. Changes in Adrenal Androgens During Puberty Suppression and Gender-Affirming Hormone Treatment in Adolescents With Gender Dysphoria.
Schagen SEE; Lustenhouwer P; Cohen-Kettenis PT; Delemarre-van de Waal HA; Hannema SE
J Sex Med; 2018 Sep; 15(9):1357-1363. PubMed ID: 30224022
[TBL] [Abstract][Full Text] [Related]
31. Daily GnRH agonist treatment effectively delayed puberty in female rats without long-term effects on sexual behavior or estrous cyclicity.
Guarraci FA; Avendano L; Kelly M; Estoesta C; Frohock B; Candelario I; Davis LK; Oevermann M; Sencherey B; Toro E; Valdivia HS; Gore AC
Physiol Behav; 2022 Oct; 254():113879. PubMed ID: 35705155
[TBL] [Abstract][Full Text] [Related]
32. Biopsychosocial Assessments for Pubertal Suppression to Treat Adolescent Gender Dysphoria.
Turban JL; Thornton J; Ehrensaft D
J Am Acad Child Adolesc Psychiatry; 2024 Apr; ():. PubMed ID: 38582366
[TBL] [Abstract][Full Text] [Related]
33. Puberty suppression and executive functioning: An fMRI-study in adolescents with gender dysphoria.
Staphorsius AS; Kreukels BP; Cohen-Kettenis PT; Veltman DJ; Burke SM; Schagen SE; Wouters FM; Delemarre-van de Waal HA; Bakker J
Psychoneuroendocrinology; 2015 Jun; 56():190-9. PubMed ID: 25837854
[TBL] [Abstract][Full Text] [Related]
34. Transgender Dependent Adolescents in the U.S. Military Health Care System: Demographics, Treatments Sought, and Health Care Service Utilization.
Van Donge N; Schvey NA; Roberts TA; Klein DA
Mil Med; 2019 May; 184(5-6):e447-e454. PubMed ID: 30325452
[TBL] [Abstract][Full Text] [Related]
35. Blood pressure dynamics after pubertal suppression with gonadotropin-releasing hormone analogs followed by estradiol treatment in transgender female adolescents: a pilot study.
Perl L; Elkon-Tamir E; Segev-Becker A; Israeli G; Brener A; Oren A
J Pediatr Endocrinol Metab; 2021 Jun; 34(6):741-745. PubMed ID: 33823098
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of Gonadotropin-Releasing Hormone Agonist Treatment to Suppress Puberty in Gender Dysphoric Adolescents.
Schagen SE; Cohen-Kettenis PT; Delemarre-van de Waal HA; Hannema SE
J Sex Med; 2016 Jul; 13(7):1125-32. PubMed ID: 27318023
[TBL] [Abstract][Full Text] [Related]
37. Clinical Follow-up of Two Adolescents Diagnosed with Gender Dysphoria.
Cesur E; Yüksel Ş; Başar K; Kaptan S
Turk Psikiyatri Derg; 2022; 33(3):214-219. PubMed ID: 36148573
[TBL] [Abstract][Full Text] [Related]
38. Urological and Gynaecological Considerations for the Use of Gonadotropin-releasing Hormone Analogues in Transgender and Nonbinary Adolescents: A Narrative Review.
Lee WG; Butler G; Carmichael P; Rashid T; Yasmin E; Morley R; Barrett J; Christopher N; Sangster P
Eur Urol Focus; 2023 Jan; 9(1):35-41. PubMed ID: 36396559
[TBL] [Abstract][Full Text] [Related]
39. Hormone Therapy in Children and Adolescents.
Abramowitz J
Endocrinol Metab Clin North Am; 2019 Jun; 48(2):331-339. PubMed ID: 31027543
[TBL] [Abstract][Full Text] [Related]
40. Daily GnRH agonist treatment delays the development of reproductive physiology and behavior in male rats.
Guarraci FA; Davis LK; Henneman EL; Toro E; Odell SE; Le N; Navarro JM; Valdivia HS; Williams I; Credeur M; Gore AC
Horm Behav; 2021 Jun; 132():104982. PubMed ID: 33957341
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
